？Brenner & Rector's the kidney, Tenth Edition> 2019-2033. e5 Copyright ⓒ 2016 by Elsevier
？KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease？ineral and Bone Disorder (CKD-MBD)
？KDIGO 2009 CKD-MBD GL KI Suppl 113
？KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Am J of Kidney Dis., 2017
？KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease Am J Kidney Dis 2003 Oct;42(4 Suppl 3):S1-201
？Clinical Practice Guideline for the Management of Chronic Kidney Disease-Mineral and Bone Disorder, Japanese Society for Dialysis Therapy and Japanese Society of Nephrology, Tokyo, Japan; Therapeutic Apheresis and Dialysis 2013; 17(3):247？-288
？The UK eCKD guide: CLINICAL PRACTICE GUIDELINE CKD-MINERAL AND BONE DISORDERS (CKD-MBD)
？Sekercioglu N, Thabane L et, al. Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis. PLoS One. 2016 Jun 8;11(6):e0156891.
？Patel L, Bernard LM et, al. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials. Clin J Am Soc Nephrol. 2016 Feb 5;11(2):232-44.
？Zhai CJ, Yang XW et, al. Efficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in patients with chronic kidney disease: a systematic review and meta-analysis. Int Urol Nephrol. 2015 Mar;47(3):527-35.
？Lorio BD et, al. Sevelamer Versus Calcium Carbonate in Incident Hemodialysis Patients: Results of an Open-Label 24-Month Randomized Clinical Trial. Clin J Am Soc Nephrol 7;487-493, 2012
？O'Neill WC, The fallacy of the calcium-phosphorus product. Kidney Int. 2007 Oct;72(7):792-6. Epub 2007 Jul 4.
？Hwang E, Choi BS et, al. Management of chronic kidney disease-mineral and bone disorder: Korean working group recommendations. Kidney Res Clin Pract. 2015 Mar;34(1):4-12
？Kwon YJ. Management of chronic kidney disease-mineral and bone disorder. 대한내과학회지: 제 86권 제 3호 2014
？Palmer SC, Hayen A et, al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011 Mar 16;305(11):1119-27.
？Naves-Diaz M, Passlick-Deetjen J et, al. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study. Nephrol Dial Transplant. 2011 Jun;26(6):1938-47.
？Cho JH, Jang HM et, al. A Real-world Cost-effectiveness Analysis of Sevelamer Versus Calcium Acetate in Korean Dialysis Patients. Clin Ther. 2018 Jan;40(1):123-134.
？Yang L, Chuen Tan S et, al. Economic Evaluation of Sevelamer versus Calcium-based Binders in Treating Hyperphosphatemia among Patients with End-stage Renal Disease in China. Clin Ther. 2016 Nov;38(11):2459-2467.e1.
？Bernard L et, al. A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom. J Med Econ. 2013;16(1):1-9.
？Hutchison AJ, Wilson RJ et, al. Lanthanum carbonate: safety data after 10？years. Nephrology (Carlton). 2016 Dec;21(12):987-994.
？Burke SK et, al. RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant. 1997 Aug;12(8):1640-4.